MiRNA-mediated EMT and CSCs in cancer chemoresistance

Dong, Bing; Li, Shiyu; Zhu, Shuangli; Yi, Ming; Luo, Suxia; Wu, Kongming

doi:10.1186/s40164-021-00206-5

Experimental Hematology & Oncology

Table 1 The role of miRNA-mediated EMT and CSCs in drug resistance

From: MiRNA-mediated EMT and CSCs in cancer chemoresistance

miRNA	Cancer type	Chemotherapy	Role in chemosensitivity	Target	Ref.
miR-375	CC	Paclitaxel	Decrease	E-cadherin	[39]
miR-514b-5p	CRC	Cisplatin and irinotecan	Decrease	CDH1, CLDN1	[40]
miR-514b-3p	CRC	Cisplatin and irinotecan	Increase	FZD4, NTN1	[40]
miR-125b	CRC	5-FU	Decrease	APC	[42]
miR-221	EC	5-FU	Decrease	DKK2	[43]
miR-93	BC	Doxorubicin	Decrease	PTEN	[44]
miR-27a	LC	Cisplatin	Decrease	RKIP	[45]
miR-155	BC	Doxorubicin and paclitaxel	Decrease	FOXO3a	[48]
	GC	Paclitaxel	Decrease	GATA3 and TP53INP1	[49]
miR-32-5p	HCC	5-FU	Decrease	PTEN	[50]
miR-509-5p	PC	Gemcitabine	Increase	Vimentin	[53]
miR-138-5p	PC	5-FU	Increase	Vimentin	[54]
miR-30a	PC	Gemcitabine	Increase	Snail	[56]
miR-153	PC	Gemcitabine	Increase	Snail	[57]
miR-363	OC	Cisplatin	Increase	Snail	[58]
miR-34	PC	Gemcitabine	Increase	Slug	[59]
miR-27b	LC	Cisplatin	Increase	Snail	[60]
miR-27b, miR-34a	PC	Docetaxel	Increase	ZEB1	[61]
miR-181a	TSCC	Cisplatin	Increase	Twist	[63]
miR-186	OC	Cisplatin	Increase	Twist	[64]
	GBM	TMZ	Increase	Twist	[65]
miR-708-3p	BC	Doxorubicin	Increase	ZEB1	[66]
miR-218	LC	Cisplatin	Increase	ZEB2, Slug	[67]
miR-200c	LC	Paclitaxel	Increase	Cathepsin L	[69]
miR-200a	BC	Cisplatin	Decrease	TP53INP1, YAP1	[72]
miR-1243	PC	Gemcitabine	Increase	SMAD4	[53]
miR-25-3p	CC	Cisplatin	Increase	Sema4C	[74]
miR-31-3p	CC	Cisplatin	Increase	Sema4C	[75]
miR-296-3p	NPC	Cisplatin	Increase	MK2	[77]
	LC	Cisplatin	Increase	PRKCA	[78]
miR-1294	OC	Cisplatin	Increase	IGF1R	[82]
miR-128-3p	CRC	Oxaliplatin	Increase	Bmi1 and MRP5	[83]
miR-5100	LC	Cisplatin	Decrease	Rab6	[84]
miR-125b	BC	Gemcitabine, Taxol	Decrease	BAK1	[86]
miR-455-3p	EC	Cisplatin	Decrease	NA	[87]
miR-27b	BC	Docetaxel	Increase	ENPP1	[89]
miR-328	CRC	5-FU, HCPT	Increase	ABCG2	[90]
miR-451	CRC	SN38	Increase	ABCB1	[91]
miR-181b	LC	Cisplatin	Increase	Notch2	[93]
miR-365	HCC	Cisplatin	Increase	RAC1	[98]
miR-485	LC	Cisplatin	Increase	CD44	[99]
miR-1246	BC	Docetaxel, epirubicin, gemcitabine	Decrease	Cyclin G2	[100]
miR-9-5p, miR-195-5p, miR-203a-3p	BC	Doxorubicin, Docetaxel	Decrease	ONECUT2	[101]
miR-129-5p	BC	Doxorubicin	Increase	SOX4	[118]
miR-532-3p	CRC	5-FU, cisplatin	Increase	ETS1 and TGM2	[119]
miR-224	CRC	5-FU	Decrease	NA	[124]
miR-145	GBM	TMZ, cisplatin	Increase	Oct4 and Sox2	[127]

5-FU 5-fluorocrail, APCadenomatous polyposis col, ABCB1 ABC subfamily B member 1, ABCG2ABC subfamily G member 2, Bak1BCL2 antagonist/killer 1, BCbreast cancer, Bmi1 B lymphoma Mo-MLV insertion region 1 homolog, CC Cervical cancer, CDH1 Cadherin 1, CLDN1 Claudin 1, CRC colorectal cancer, EC esophageal cancer, ENPP1 ectonucleotide pyrophosphatase/phosphodiesterase 1, ETS1 V-Ets avian erythroblastosis virus E26 oncogene homolog 1, FOXO3a Forkhead Box O3, FZD4 frizzled class receptor 4, GATA3 GATA binding protein 3, GBM Glioblastoma, GC gastric cancer, HCPT hydroxycamptothecine, IGF1R insulin like growth factor 1 receptor, LC lung cancer, MK2 MAPK activated protein kinase 2, MRP5 multidrug resistant protein 5, NA not acquired, NIN1 Netrin 1, NPC Nasopharyngeal carcinoma, OC ovarian cancer, Oct4 Octamer-binding protein 4, ONECUT2 one cut homeobox 2, PC Pancreatic cancer, PRKCA Protein kinase C alpha, RAC1 Ras-related C3 botulinum toxin substrate 1, Rab6 Ras-related protein Rab-6a, RKIP Raf kinase inhibitory protein, SN38 7-ethyl-10-hydroxycamptothecin, SOX SRY-box transcription factor, TGM2 transglutaminase 2, TMZ temozolomide, TP53INP1 tumor protein P53 inducible nuclear protein 1, YAP1 Yes associated protein 1

Back to article page

ISSN: 2162-3619

Contact us

Submission enquiries: journalsubmissions@springernature.com